NurExone Biologic

Home
Israel
Haifa
NurExone Biologic

Developing a revolutionary exosome-based drug platform to treat damage in the CNS

25/10/2026

Exosomes are moving toward the mainstream. Can manufacturing keep up?

From regenerative therapies to aesthetics, growing interest in exosomes raises a critical question: how do we produce them at scale while maintaining consistency and quality?

NurExone CEO Lior Shaltiel, PhD Shaltiel explores why manufacturing may be almost as important as the science itself in a new article for Life Science Daily News.

➡️ Read more:

Exosome manufacturing may be the key to scale. Learn why process control, characterization and GMP matter as the field matures.

11/10/2026

Optic nerve damage can lead to permanent vision loss, with few options to repair the damage

Our latest preclinical results from the Goldschleger Eye Institute at Sheba Medical Center, Tel Hashomer Center showed improved retinal responses following ExoPTEN treatment in an animal model of optic nerve injury.

These encouraging findings support our plans to advance the program to a larger-animal study, an important step toward potential human clinical evaluation.

Read more: https://www.globenewswire.com/news-release/2026/10/09/3378353/0/en/nurexone-advances-optic-nerve-injury-program-toward-larger-animal-study-following-positive-preclinical-results.html

17/09/2026

At our Annual General and Special Meeting, shareholders approved all resolutions, including a share consolidation resolution as an enabling step in our capital markets strategy.

A corporate update also accompanied the AGM results.

➡️ Read here: https://www.globenewswire.com/news-release/2026/09/16/3363531/0/en/nurexone-announces-voting-results-of-annual-general-and-special-meeting-of-shareholders-and-provides-corporate-update.html

15/09/2026

Through an MOU with Nanopass Technologies Ltd., we will evaluate its clinically established MicronJet™ technology with NurExone’s exosome formulations for optic nerve and skincare applications. The collaboration brings together our exosome expertise with NanoPass’s precision-delivery technology.

ExoPTEN for acute spinal cord injury remains our lead development program and continues to advance separately on its existing path.

https://www.globenewswire.com/news-release/2026/09/14/3361533/0/en/nurexone-and-nanopass-technologies-ltd-to-collaborate-on-integrated-exosome-delivery-approach-for-regenerative-eye-and-skin-applications.html

08/09/2026

25/08/2026

Sign up here!

Register for the webinar: https://small-microcap.eu/event/webinar-from-a-cutting-edge-research-trend-to-a-multi-billion-market-the-investment-potential-of-exosomes/

September 1st at 5:00 PM CEST | 11:00 AM EDT

29/07/2026

We are pleased to welcome David Stolick to NurExone's Board of Directors.

David succeeds the late James Richardson, whose lasting contributions helped shape NurExone during its formative years.

Read the full announcement: https://www.globenewswire.com/news-release/2026/07/28/3334841/0/en/corporate-updates-nurexone-appoints-mr-david-stolick-to-the-board-of-directors.html

25/06/2026

Exo-Top, NurExone’s wholly owned U.S. subsidiary, entered into a binding MOU with ExoLyra for the distribution of naïve MSC-derived exosome products in Mexico.

The agreement marks Exo-Top’s first structured commercial entry and supports NurExone’s dual-track strategy: near-term exosome commercialization alongside continued ExoPTEN therapeutic development.

Read More: https://www.globenewswire.com/news-release/2026/06/24/3317189/0/en/exo-top-nurexone-s-wholly-owned-u-s-subsidiary-enters-into-binding-mou-for-na%c3%afve-exosome-distribution-in-mexico.html

Learn more about Exo-Top: https://nurexone.com/exo-top/

15/06/2026

Geekonomy pairs two ideas that are deeply connected: “geek” and “economy,” reflecting how scientific curiosity, technical depth, and entrepreneurship help drive economic growth.

In this episode of the Geekonomy podcast, Lior Shaltiel, PhD joins Reem Sherman to discuss one of medicine’s most complex challenges: central nervous system injuries, including spinal cord injury and optic nerve damage, and NurExone’s work with exosome-based regenerative medicine.

Many thanks for hosting us.

Listen and enjoy (Hebrew):

ד״ר ליאור שאלתיאל הוא מנכ״ל חברת נוראקסון, שמטפלת באחד האתגרים המורכבים ביותר של עולם הרפואה: פגיעה במערכת העצבים המרכזית, כמו פגיעות בחוט השדרה או בעצב הראיה, באמצע...

01/06/2026

We announced our Q1 2026 financial results and corporate update.

Highlights include:

✅ Technion proteomic analysis supporting our regulatory roadmap

✅ Exo-Top sublicense supporting the Company’s U.S. strategy

✅ BioXtek LOI for potential U.S. exosome manufacturing and commercialization

✅ ExoPTEN and platform IP progress in Australia and Korea

✅ Completion of a March private placement strengthening the Company’s balance sheet and supporting strategic initiatives

Read the full announcement: https://www.globenewswire.com/news-release/2026/06/01/3304336/0/en/nurexone-announces-first-quarter-2026-financial-results-and-provides-corporate-update.html

Address

Haifa

Website

https://nurexone.com/

Alerts

Be the first to know and let us send you an email when NurExone Biologic posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.